Updated:
QLT
QLT is a biotechnology company founded in 1981 in Vancouver, Canada. It develops and commercializes ocular products for patients and clinicians.
QLT
QLT is a biotechnology company founded in 1981 in Vancouver, Canada. It develops and commercializes ocular products for patients and clinicians. The company focuses on a synthetic retinoid program for inherited retinal diseases.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Vancouver, Canada
Sector focus
Frequently asked questions
What is QLT's current business model?
QLT shifted from drug development to a royalty and licensing model after selling its commercial operations. It now generates revenue from milestone payments and royalty streams from therapies it previously developed or in-licensed (public record). The firm does not actively invest in new R&D.
Who makes investment decisions at QLT?
Investment decisions are made by QLT's executive team, which has not been publicly named in recent years. The firm's public filings indicate a small leadership group focused on royalty asset management and financial oversight.
What therapy platforms does QLT hold royalties on?
QLT's primary known royalty stream was from Visudyne (verteporfin) for wet AMD, licensed to Novartis (public record). Other legacy assets include dermatology treatments and photodynamic therapy compounds, though specific current holdings are not publicly updated.
Does QLT invest in new biotechnology companies?
No — QLT no longer makes active investments or product development. Its post-sale model focuses on managing existing royalty and licensing agreements without deploying capital into new ventures or partnerships.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: